In this series, we interviewed Dana-Farber Cancer Institute leaders, past and present, to gain perspective on progress at the Institute over the decades and some of the unique elements of our organization and culture. Here, we look back at some of the scientific achievements that have led to substantial improvements in cancer patient outcomes.
Recorded in 2022.
Featuring:
- George Demetri, MD, Director, Sarcoma Center, SVP for Experimental Therapeutics, Institute Physician, Dana-Farber Cancer Institute
- Charles D. Stiles, PhD, Deputy Director, Mahoney Center for Neuro Oncology, Dana-Farber Cancer Institute
- Pasi A. Jänne, MD, PhD, Director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
- Stephen E. Sallan, MD, Quick Family Chair in Pediatric Oncology, Chief of Staff Emeritus, Dana-Farber Cancer Institute
- Sara M. Tolaney, MD, MPH, Chief, Division of Breast Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute
- Gordon J. Freeman, PhD, Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School
- Laurie H. Glimcher, MD, President and CEO, Dana-Farber Cancer Institute
- William C. Hahn, MD, PhD, Executive Vice President and Chief Operating Officer, Dana-Farber Cancer Institute
